Varlilumab: A Deep Dive into CDX-1127 and its Mechanism This therapeutic (formerly known as PRT-052) represents a novel immunotherapeutic approach targeting the CD27 receptor. Its mechanism relies on association to https://www.targetmol.com/compound/varlilumab